Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations
CA 2268278 A1 · Owner: Somatogen, Inc. · Inventors: Frye, Christopher C.; Hershberger, Charles L.; Best, Elaine A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to recombinant hemoglobin solutions containing reduced amounts of protoporphyrin IX and to methods of producing such hemoglobin solutions. The methods are accomplished by overexpressing the hemH gene in a suitable host cell or by increasing the production of hemH in a host cell, for example, by integration of the hemH gene into the chromosome of the host cell or by inserting multiple copies of the gene in host cells naturally having a hemH gene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 17, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 17, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 17, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.